Medtronic linq insertable cardiac monitor detects 10 times more atrial fibrillation in ischemic stroke patients at three years compared to standard of care

Isc23: late-breaking results from stroke af study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients dublin and dallas , feb. 8, 2023 /prnewswire/ -- medtronic (nyse: mdt) today announced late-breaking clinical data from the stroke af clinical study, which showed large and small vessel disease stroke patients had a 10-fold increase in af detection with the reveal linq™ insertable cardiac monitor (icm) at three years compared to patients randomized to standard of care who did not receive continuous, long-term monitoring. the latest results, presented today as a late-breaking clinical trial at the american stroke association's international stroke conference (isc) 2023, build on the stroke af study 12-month primary endpoint results published in jama in june 2021.
MDT Ratings Summary
MDT Quant Ranking